Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 553.e1-553.e11

  Scott, Heather A ^a,c   Gebhardt, Florian M ^a   Mitrovic, Ann D ^b   Vandenberg, Robert J ^b   Dodd, Peter R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Sydney IVF   (Australia)

Author keywords

Alternative splicing; Alzheimer's disease; Excitatory amino acid transporter 2; Excitotoxicity; Glutamate uptake; Splice variant

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ASTROCYTE; AUTOPSY; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS LAEVIS;

EID: 79952899104     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.03.008     Document Type: Article

References (47)

1. Beart P.M., O'Shea R.D. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br. J. Pharmacol 2007, 150:5-17.
2. Beckstrøm H., Julsrud L., Haugeto ø., Dewar D., Graham D.I., Lehre K.P., Storm-Mathisen J., Danbolt N.C. Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J. Neurosci. Res. 1999, 55:218-229.
3. Beschorner R., Simon P., Schauer N., Mittelbronn M., Schluesener H.J., Trautmann K., Dietz K., Meyermann R. Reactive astrocytes and activated microglial cells express EAAT1, but not EAAT2, reflecting a neuroprotective potential following ischaemia. Histopathology 2007, 50:897-910.
4. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
5. Buracchio T., Arvanitakis Z., Gorbien M. Dementia with Lewy bodies: current concepts. Dement. Geriatr. Cogn. Disord 2005, 20:306-320.
6. Chen W., Aoki C., Mahadomrongkul V., Gruber C.E., Wang G.J., Blitzblau R., Irwin N., Rosenberg P.A. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J. Neurosci 2002, 22:2142-2152.
7. Cross A.J., Slater P., Simpson M.D.C., Royston C., Deakin J.F.W., Perry R.H., Perry E.K. Sodium dependent D-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases. Neurosci. Lett. 1987, 79:213-217.
8. Danbolt N.C. Glutamate uptake. Prog. Neurobiol 2001, 65:1-105.
9. Dodd P.R., Hardy J.A., Baig E.B., Kidd A.M., Bird E.D., Watson W.E.J., Johnston G.A.R. Optimization of freezing, storage, and thawing conditions for the preparation of metabolically active synaptosomes from frozen rat and human brain. Neurochem. Pathol 1986, 4:177-198.
10. Flowers J.M., Powell J.F., Leigh P.N., Andersen P., Shaw C.E. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with Amyotrophic Lateral Sclerosis. Ann. Neurol 2001, 49:643-649.
11. Francis P.T. Pyramidal neurone modulation: a therapeutic target for Alzheimer's disease. Neurodegeneration 1996, 5:461-465.
12. Francis P.T. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18(suppl 1):S15-S21.
13. Fray A.E., Ince P.G., Banner S.J., Milton I.D., Usher P.A., Cookson M.R., Shaw P.J. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. Eur. J. Neurosci 1998, 10:2481-2489.
14. Gendreau S., Voswinkel S., Torres-Salazar D., Lang N., Heidtmann H., Detro-Dassen S., Schmalzing G., Hidalgo P., Fahlke C. A trimeric quaternary structure is conserved in bacterial and human glutamate transporters. J. Biol. Chem 2004, 279:39505-39512.
15. Guo H., Lai L., Butchbach M.E., Lin C.L. Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death. Mol. Cell. Neurosci 2002, 21:546-560.
16. Hardy J.A., Cowburn R.F., Barton A.J.L., Reynolds G.P., Lofdahl E., O'Carroll A.-M., Wester P., Winblad B. Region-specific loss of glutamate innervation in Alzheimer's disease. Neurosci. Lett 1987, 73:77-80.
17. Jacob C.P., Koutsilieri E., Bartl J., Neuen-Jacob E., Arzberger T., Zander N., Ravid R., Roggendorf W., Riederer P., Grunblatt E. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J. Alzheimers Dis 2007, 11:97-116.
18. Kalandadze A., Wu Y., Fournier K., Robinson M.B. Identification of motifs involved in endoplasmic reticulum retention-forward trafficking of the GLT-1 subtype of glutamate transporter. J. Neurosci 2004, 24:5183-5192.
19. Kleczkowski A. The transformation of local lesion counts for statistical analysis. Ann. Appl. Biol 1949, 36:139-152.
20. Lauriat T.L., McInnes L.A. EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders. Mol. Psychiatry 2007, 12:1065-1078.
21. Lauriat T.L., Richler E., McInnes L.A. A quantitative regional expression profile of EAAT2 known and novel splice variants reopens the question of aberrant EAAT2 splicing in disease. Neurochem. Int 2007, 50:271-280.
22. Li S., Mallory M., Alford M., Tanaka S., Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol 1997, 56:901-911.
23. Liang Z., Valla J., Sefidvash-Hockley S., Rogers J., Li R. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J. Neurochem 2002, 80:807-814.
24. Lin C.L., Bristol L.A., Jin L., Dykes-Hoberg M., Crawford T., Clawson L., Rothstein J.D. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in Amyotrophic Lateral Sclerosis. Neuron 1998, 20:589-602.
25. Maragakis N.J., Dykes-Hoberg M., Rothstein J.D. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol 2004, 55:469-477.
26. Masliah E., Alford M., Deteresa R., Mallory M., Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol 1996, 40:759-766.
27. McLean R.A., Welch B.L. A common error in assessing the significance of percentage change in neuropharmacology. J. Pharm. Pharmacol 1971, 23:643-645.
28. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer-s disease. Neurology 1991, 41:479-486.
29. Modrek B., Resch A., Grasso C., Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res. 2001, 29:2850-2859.
30. Münch C., Schwalenstöcker B., Hermann C., Cirovic S., Stamm S., Ludolph A., Meyer T. Differential RNA cleavage and polyadenylation of the glutamate transporter EAAT2 in the human brain. Brain Res. Mol. Brain Res. 2000, 80:244-251.
31. Münch C., Zhu B.G., Mink A., Seefried U., Riepe M.W., Ludolph A.C., Meyer T. Chemical hypoxia facilitates alternative splicing of EAAT2 in presymptomatic APP23 transgenic mice. Neurochem. Res. 2008, 33:1005-1010.
32. Ohnuma T., Suzuki T., Arai H. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:889-894.
33. Pow D.V., Cook D.G. Neuronal expression of splice variants of "glial" glutamate transporters in brains afflicted by Alzheimer's disease: unmasking an intrinsic neuronal property. Neurochem. Res. 2009, 34:1748-1757.
34. Rothstein J.D. Excitotoxicity hypothesis. Neurology 1996, 47(suppl 2):S19-S25.
35. Schlag B.D., Vondrasek J.R., Munir M., Kalandadze A., Zelenaia O.A., Rothstein J.D., Robinson M.B. Regulation of the glial Na+-dependent glutamate transporters by cyclic AMP analogs and neurons. Mol. Pharmacol 1998, 53:355-369.
36. Simpson J.E., Ince P.G., Lace G., Forster G., Shaw P.J., Matthews F., Savva G., Brayne C., Wharton S.B. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging 2010, 31:578-590. MRC Cognitive Function and Ageing Neuropathology Study Group.
37. Tannenberg R.K., Scott H.L., Tannenberg A.E., Dodd P.R. Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE ε4. Neurochem. Int. 2006, 49:631-639.
38. Thal D.R. Excitatory amino acid transporter EAAT-2 in tangle-bearing neurons in Alzheimer's disease. Brain Pathol 2002, 12:405-411.
39. Utsunomiya-Tate N., Endou H., Kanai Y. Tissue specific variants of glutamate transporter GLT1. FEBS Lett. 1997, 416:312-316.
40. van Landeghem F.K., Weiss T., Oehmichen M., von Deimling A. Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J. Neurotrauma 2006, 23:1518-1528.
41. Vandenberg R.J., Mitrovic A.D., Chebib M., Balcar V.J., Johnston G.A.R. Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol. Pharmacol 1997, 51:809-815.
42. Walton H.S., Dodd P.R. Glutamate-glutamine cycling in Alzheimer's disease. Neurochem. Int. 2007, 50:1052-1066.
43. Walton H.S., Gebhardt F.M., Innes D.J., Dodd P.R. Analysis of multiple exon-skipping mRNA splice variants using SYBR Green real-time RT-PCR. J. Neurosci. Methods 2007, 160:294-301.
44. Wilson J.M., Khabazian I., Pow D.V., Craig U.K., Shaw C.A. Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC. Neuromolecular Med. 2003, 3:105-118.
45. Winer B.J., Brown D.R., Michels K.M. Statistical Principles in Experimental Design 1991, McGraw-Hill, Sydney.
46. Yernool D., Boudker O., Jin Y., Gouaux E. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 2004, 431:811-818.
47. Yi J.H., Hazell A.S. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem. Int. 2006, 48:394-403.